Pidilizumab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody targeting human PD-1 (programmed cell death 1; PDCD1). It has immunomodulating and antitumor activities and can be used in treatment of metastatic melanoma. MW :144.48 KD.